OnKure Therapeutics (OKUR) and Its Peers Critical Contrast

OnKure Therapeutics (NASDAQ:OKUR) is one of 1,044 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare OnKure Therapeutics to related companies based on the strength of its valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and risk.

Risk & Volatility

OnKure Therapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Comparatively, OnKure Therapeutics’ competitors have a beta of 1.00, indicating that their average stock price is 0% more volatile than the S&P 500.

Profitability

This table compares OnKure Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-51.17%	-47.11%
OnKure Therapeutics Competitors	-3,610.82%	-270.26%	-33.18%

Insider and Institutional Ownership

91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 17.9% of OnKure Therapeutics shares are owned by insiders. Comparatively, 13.8% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for OnKure Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	0	0	2	1	3.33
OnKure Therapeutics Competitors	7558	20801	48343	1185	2.55

OnKure Therapeutics presently has a consensus target price of $37.50, suggesting a potential upside of 125.90%. As a group, “Pharmaceutical preparations” companies have a potential upside of 74.58%. Given OnKure Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe OnKure Therapeutics is more favorable than its competitors.

Earnings and Valuation

This table compares OnKure Therapeutics and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
OnKure Therapeutics	N/A	-$77.39 million	-1.36
OnKure Therapeutics Competitors	$1.71 billion	$155.47 million	-5.04

OnKure Therapeutics’ competitors have higher revenue and earnings than OnKure Therapeutics. OnKure Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

OnKure Therapeutics beats its competitors on 9 of the 13 factors compared.

About OnKure Therapeutics

Reneo Pharmaceuticals Inc.is a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Inc.is based in SAN DIEGO.